The Claim
In individuals with gout, pyrazinamide induces heightened proximal tubular reabsorption of uric acid, leading to elevated serum urate levels despite normal or low uric acid production.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with gout, the drug pyrazinamide causes the kidneys to reabsorb more uric acid from urine back into the blood, resulting in higher blood uric acid levels even when the body is not producing excess uric acid.
See the scientific wording
In individuals with gout, the renal response to pyrazinamide—known to enhance uric acid reabsorption—indicates heightened proximal tubular reabsorption capacity, contributing to elevated serum urate levels despite normal or low uric acid production.
In people with gout, pyrazinamide blocks the kidney's ability to remove uric acid by stopping its secretion into urine, while simultaneously increasing how much uric acid the kidney pulls back from urine into the blood. This double effect causes uric acid to build up in the blood even when the body isn't making more than normal.
What the research says
1 studyStudy: Renal handling of uric acid in gout by means of the pyrazinamide and probenecid tests.
In people with gout, their kidneys hold onto too much uric acid when given pyrazinamide, which helps explain why their blood uric acid stays high even if their body isn’t making extra. The study shows this kidney behavior is a key reason for gout.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.